Cannabigerol, or CBG, is a minor cannabinoid with non-intoxicating effects. It is present in trace amounts in most strains, starting as cannabigerolic acid, or CBGA, before converting to other cannabinoids like THCA and CBDA.
Research is ongoing to uncover CBG’s potential to treat neurological disorders, including Huntington’s disease, Parkinson’s disease and multiple sclerosis, as well as inflammatory bowel disease. Other studies are underway to investigate its antibacterial properties.